Table of Contents
Charles Ruck, partner and global chair of the Corporate Department at Latham & Watkins and a 33-year veteran of the firm, spoke to Onyx on the sidelines of the Jefferies Global Healthcare Conference in London about regulation on both sides of the Atlantic, most favored nation pricing, and when biotechs should reveal their targets.
Charles Ruck, Global Chair of the Corporate Department, Latham & Watkins
On the sidelines of the Jefferies Global Healthcare Conference, London, November 17, 2026
Tell us about Latham & Watkins and how you fit into the global healthcare world.
Our healthcare group have centers of excellence in Boston, Austin, Texas, San Diego, Silicon Valley, here in London, and also on the continent in Paris and Germany.
We represent clients across the spectrum, from biotech to pharma to diagnostics to healthcare, insurers and the like. We do that with a team that's balanced between transactional lawyers, raising capital, and buying and selling businesses, a dedicated licensing team, intellectual property group, and a regulatory group.

How is Europe's new regulatory environment affecting your clients?
It's been really tough times, it feels like, in Europe. I think our U.S. clients are feeling it when they decide to come to Europe, too: the whole new encyclopedia of rules that they need to learn.

But I would also say it's been tougher in the United States the last few years, too, with an FDA that's, I think, frustrated some venture capitalists by slowing things down and insisting on more data. So I think it's tough all over.

Do you get consulted much on most favored nation pricing?
We did. That is tricky business, and it mixes geopolitics with healthcare, which makes it even trickier.
What would you tell younger biotech CEOs who don't have big corporate law behind them?
Well, I guess the first thing is if you're worried about most favored nation pricing, you're already in a pretty good set of company, because you're selling your products and you're navigating different countries' regulatory systems. So, the first thing is congratulations.
The second thing that I think a lot of companies think about is where they want to go based on the rules and regulations that they're going to have to follow. I know it sounds self-serving: you're going to need a good set of lawyers and consultants to navigate those rules.
And the one thing that I know is sure is the second you think you have it all figured out, it'll shift. And so it's a dynamic process.
The second you think you have it all figured out, it’ll shift.
A lot of biotechs wait until the last minute to disclose their targets. How do you see that decision?
The decision not to pull up the curtain is a little more trade secret law than it is patent law.
And it seems to me that if you have a proper patent portfolio that's been well thought through, it's defensible whether you pull up the curtain or not. But I do know that kind of for surprise on the market and some competitive reasons, you don't pull up the curtain.
When you look at a company, what tells you it's going to go far?
Personally, I look to the management team and the science behind it.
I fully admit I'm not great at discerning the science and the patents and the molecules, but if the right people are backing the therapy, I think that's the way I make my decisions.
If the right people are backing the therapy, I think that’s the way I make my decisions.
Is there a piece of work from your career that stands out?
Look, I run a team, and some of the things that we have done over the years make me really proud.
What I love about life sciences and healthcare is that we're all trying to do well for our families, but we're doing good for people in need, whether they're sick, or we can extend a life. And so in my mind, all of healthcare law is a really good story about working hard and making a difference.
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

Comments